Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 361.90
-7.45 (-2.02%)
At close: Apr 21, 2026
Cohance Lifesciences Market Cap
Cohance Lifesciences has a market cap or net worth of 138.18 billion as of April 21, 2026. Its market cap has decreased by -51.11% in one year.
Market Cap
138.18B
Enterprise Value
140.05B
Revenue
10.79B
Ranking
n/a
PE Ratio
227.87
Stock Price
361.90
Market Cap Chart
Since March 9, 2020, Cohance Lifesciences's market cap has increased from 33.71M to 138.18B, an increase of 409,878.49%. That is a compound annual growth rate of 289.28%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 21, 2026 | 138.18B | -31.67% |
| Dec 31, 2025 | 202.22B | -30.24% |
| Dec 31, 2024 | 289.89B | 57.55% |
| Dec 29, 2023 | 184.00B | 46.05% |
| Dec 30, 2022 | 125.98B | 0.33% |
| Dec 31, 2021 | 125.56B | 9.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Mar 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| J. B. Chemicals & Pharmaceuticals | 319.99B |
| AstraZeneca Pharma India | 213.00B |
| Granules India | 164.48B |
| Rubicon Research | 152.81B |
| Jubilant Pharmova | 143.25B |
| Caplin Point Laboratories | 133.34B |
| CORONA Remedies | 103.87B |
| Viyash Scientific | 91.18B |